右心室心肌梗死时使用硝酸酯类的不良事件:系统评价与荟萃分析
该系统评价与荟萃分析检索6个数据库至2022年5月,纳入5项研究(n=1113),评估右心室心肌梗死(RVMI)时使用硝酸酯类的不良事件。对舌下硝酸甘油400 μg的荟萃分析(2项研究,n=1050)显示,合并下壁和右心室心肌梗死时不良事件相对风险为1.31(95%CI 0.81-2.12,p=0.27),无统计学显著差异,绝对效应为每100次治疗增加3例不良事件,敏感性分析结果稳健。RVMI组未发生心脏骤停和死亡。作者认为AHA和ESC的禁忌证缺乏证据支持,硝酸酯类不良事件短暂且易于处理,是RVMI时可考虑的治疗方式;主要局限为所有研究均合并下壁和RVMI、未评估获益、证据确定性极低。
要点
- 合并下壁和RVMI患者舌下硝酸甘油400 μg后不良事件相对风险1.31(95%CI 0.81-2.12,p=0.27),无统计学显著差异。
- 绝对效应为每100次治疗增加3例不良事件,敏感性分析结果稳健。
- RVMI组未发生心脏骤停和死亡。
- 作者认为AHA和ESC的禁忌证缺乏证据支持,硝酸酯类不良事件短暂且易于处理,是RVMI时可考虑的治疗方式。
- 证据确定性极低,所有研究均合并下壁和RVMI,未评估获益。
适用人群与场景
- 合并下壁和右心室心肌梗死(RVMI)的患者(所有纳入研究均为此类人群)。
处置流程与药物剂量
- 舌下硝酸甘油400 μg用于合并下壁和RVMI患者(荟萃分析评估的干预)。
研究设计与关键结果
- 系统评价与荟萃分析,检索PubMed、Embase、MEDLINE Complete、Cochrane CENTRAL Register、CINAHL和Google Scholar共6个数据库(2022年5月),纳入5项研究(n=1113)。
- 结局包括血流动力学、GCS、晕厥、心脏骤停和死亡;RVMI组未发生心脏骤停和死亡。
- 舌下硝酸甘油400 μg的荟萃分析(2项研究,n=1050):合并下壁和RVMI时不良事件相对风险1.31(95%CI 0.81-2.12,p=0.27),无统计学显著差异,绝对效应为每100次治疗增加3例不良事件,敏感性分析结果稳健。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析(PROSPERO注册号CRD42020172839)。
- 证据确定性极低。
- 局限:所有研究均合并下壁和RVMI;未评估获益;证据确定性极低。
对床旁实践的改变
- 作者认为AHA和ESC关于RVMI禁用硝酸酯类的禁忌证缺乏证据支持。
- 作者认为硝酸酯类不良事件短暂且易于处理,是RVMI时可考虑的治疗方式。
指南或共识出处
- 美国心脏协会(AHA)和欧洲心脏病学会(ESC)指南推荐RVMI时不予硝酸酯类药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The current guidelines of the American Heart Association (AHA) and European Society of Cardiology (ESC) recommend that when right ventricular myocardial infarction (RVMI) is present patients are not administered nitrates, due to the risk that decreasing preload in the setting of already compromised right ventricular ejection fraction may reduce cardiac output and precipitate hypotension. The cohort study (n=40) underlying this recommendation was recently challenged by new studies suitable for meta-analysis (cumulatively, n=1050), suggesting that this topic merits systematic review.
METHODS: The protocol was registered on PROSPERO and published in Evidence Synthesis. Six databases were systematically searched in May 2022: PubMed, Embase, MEDLINE Complete, Cochrane CENTRAL Register, CINAHL and Google Scholar. Two investigators independently assessed for quality and bias and extracted data using Joanna Briggs Institute tools and methods. Risk ratios and 95% CIs were calculated, and meta-analysis performed using the random effects inverse variance method.
RESULTS: Five studies (n=1113) were suitable. Outcomes included haemodynamics, GCS, syncope, arrest and death. Arrest and death did not occur in the RVMI group. Meta-analysis was possible for sublingual nitroglycerin 400 μg (2 studies, n=1050) and found no statistically significant difference in relative risk to combined inferior and RVMI at 1.31 (95% CI 0.81 to 2.12, p=0.27), with an absolute effect of 3 additional adverse events per 100 treatments. Results remained robust under sensitivity analysis.
CONCLUSIONS: This review suggests that the AHA and ESC contraindications are not supported by evidence. Key limitations include all studies having concomitant inferior and RVMI, not evaluating beneficial effects and very low certainty of evidence. As adverse events are transient and easily managed, nitrates are a reasonable treatment modality to consider during RVMI on current evidence.
PROSPERO REGISTRATION NUMBER: CRD42020172839.
参考来源
- Wilkinson-Stokes M, Betson J, Sawyer S, et al. Adverse events from nitrate administration during right ventricular myocardial infarction: a systematic review and meta-analysis. Emerg Med J. 2022. PMID: 36180168. doi:10.1136/emermed-2021-212294
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。